CARLSMED, INC.
For the period ended Mar 31, 2026. Filed May 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 5, 2026
CARL$14.52-5.2%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
(in thousands, except share and per share amounts)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Revenue | $16,116 | $10,189 |
| Cost of sales | 3,691 | 2,553 |
| Gross profit | 12,425 | 7,636 |
| Operating expenses: | ||
| Research and development | 5,178 | 3,150 |
| Sales and marketing | 10,297 | 6,739 |
| General and administrative | 6,226 | 3,466 |
| Total operating expenses | 21,701 | 13,355 |
| Loss from operations | (9,276) | (5,719) |
| Other income (expense): | ||
| Interest expense | (311) | (357) |
| Interest income | 891 | 380 |
| Change in fair value of warrant liabilities | — | (33) |
| Total other income (expense), net | 580 | (10) |
| Net loss and comprehensive loss | (8,696) | (5,729) |
| Deemed dividend to preferred stockholders | — | (584) |
| Net loss attributable to common stockholders | $(8,696) | $(6,313) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.32) | $(1.47) |
| Weighted-average number of common shares used to compute basic and diluted net loss per share | 26,835,841 | 4,299,492 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.